12 February 2026 - A drug selected for the latest round of Medicare drug price negotiations stands to get dropped because a lower-cost biosimilar version of it is slated to hit the market this year.

The Trump administration recently unveiled the list of drugs picked for the third cycle of the Medicare Drug Price Negotiation Program, a Biden era plan that slashes the costs of some of the most widely used and expensive medicines through talks with manufacturers. 

Among the 15 drugs selected was Genentech's Xolair, a popular asthma treatment that has been on the market since 2003 and will soon face competition when a biosimilar version launches.

Read Bloomberg Law article